Wegovy Side Effects: Comprehensive Safety Information

Wegovy (semaglutide) is prescribed for chronic weight management and, for some adults with overweight or obesity and established cardiovascular disease, to reduce the risk of major cardiovascular events. Its safety information depends on the formulation, dose, population, and duration studied. The current Wegovy prescribing information is the best starting point for product-specific warnings.

Understanding Wegovy's Mechanism and Safety Profile

Wegovy is semaglutide, the same active ingredient used in Ozempic, but the products have different indications and dosing instructions. This guide primarily describes adult 2.4-mg weekly injection data for weight management. Daily tablets have a separate schedule: 1.5 mg for days 1–30, 4 mg for days 31–60, 9 mg for days 61–90, then 25 mg daily. The 7.2-mg weekly injection is a conditional adult weight-management option, not the dose studied in the original pooled trials below. These formulations and doses should only be changed under a prescriber's direction.

Wegovy injection also has an indication for adults with noncirrhotic MASH, a form of metabolic liver disease, with moderate-to-advanced fibrosis (F2–F3), under accelerated approval. Pediatric weight-management evidence applies from age 12 in patients with obesity. The 7.2-mg dose and tablets are not established for pediatric or MASH use; cardiovascular-risk-reduction injection maintenance is 1.7 or 2.4 mg, with 2.4 mg recommended. Discuss the specific indication and formulation when interpreting side-effect information.

Semaglutide activates GLP-1 receptors involved in appetite and satiety and slows gastric emptying. Those effects can reduce food intake and support weight loss, while also making nausea, vomiting, diarrhea, constipation, or abdominal discomfort more likely for some people. A slower or delayed increase may be appropriate when a person is not tolerating a dose, but a prescriber should direct that change.

The label and clinical studies describe common reactions as well as uncommon but important risks. The numbers below come from particular trials and formulations; they describe groups, not a promise about what will happen after an individual injection.

Gastrointestinal Side Effects: The Most Common Concern

Gastrointestinal reactions are the most frequently reported side effects in adult Wegovy injection trials. Table 3 of the official label reports the following results from three pooled adult weight-management trials: 2,116 participants received Wegovy 2.4 mg and 1,261 received placebo, with up to 68 weeks of treatment and seven weeks of off-drug follow-up.

These are study-period participant rates, not the chance of a symptom after one injection. Symptoms are often more noticeable during dose escalation and can improve over time, but their timing varies. Constipation may last longer than nausea or vomiting. Repeated vomiting, inability to keep fluids down, severe pain, or symptoms that do not settle deserve prompt clinical advice.

Smaller meals, eating slowly, stopping when comfortably full, and choosing bland, lower-fat foods while the stomach is unsettled can be practical measures. Food triggers vary. Avoid lying down after eating, and ask a clinician about fluid intake if you have kidney, heart, or other conditions that limit fluids.

STEP Trial Safety Data: What the Studies Show

The pooled adult 2.4-mg injection data underlying the label came from three placebo-controlled weight-management trials with up to 68 weeks of treatment. The populations and trial designs were not identical, so their rates should not be treated as one universal experience for every person using Wegovy.

In those pooled studies, gastrointestinal reactions were reported by 73% of Wegovy-treated participants and 47% of placebo participants. Severe gastrointestinal reactions occurred in 4.1% and 0.9%, respectively. Discontinuation because of any adverse reaction occurred in 6.8% versus 3.2%, while discontinuation specifically because of a gastrointestinal reaction occurred in 4.3% versus 0.7%. These are different outcomes: an event frequency is not the same as a serious-event rate or a discontinuation rate.

A pooled STEP 1–3 analysis found that most gastrointestinal events were mild or moderate and occurred during or shortly after escalation. Importantly, substantial weight loss also occurred in people without these symptoms: the authors' mediation analysis estimated that gastrointestinal events accounted for less than one percentage point of the additional weight loss versus placebo. Feeling sick is not a requirement for the medicine to work. Severe or persistent symptoms still need assessment.

For a separate long-term data point, the 104-week STEP 5 trial included 304 adults without diabetes who received semaglutide 2.4 mg or placebo with behavioral intervention. Weight change averaged -15.2% versus -2.6%; gastrointestinal events occurred in 82.2% versus 53.9% and were mostly mild or moderate. The study supports sustained average weight loss over that period, not lifelong safety or guaranteed tolerability. Read the STEP 5 report for its population and duration.

Serious Warnings: Pancreatitis, Thyroid, and Gallbladder Risks

Wegovy has one boxed warning, concerning thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or a prior serious allergic reaction to semaglutide or its ingredients. Seek clinical advice for a new neck lump, swelling, persistent hoarseness, or trouble swallowing. The label says routine calcitonin testing or thyroid ultrasound has uncertain value for early detection; follow-up should reflect your individual findings and history.

Severe or persistent abdominal pain, sometimes extending to the back, with or without vomiting, can be a sign of pancreatitis. In adult weight-reduction trials, adjudicated acute pancreatitis occurred in 4 Wegovy-treated patients (0.2 cases per 100 patient-years) and 1 placebo-treated patient (less than 0.1 cases per 100 patient-years). These are exposure-adjusted rates, not percentages of patients. Stop Wegovy and seek prompt medical assessment if this occurs; severe pain or illness warrants emergency evaluation. Discuss any previous pancreatitis or gallbladder problems with the prescriber before treatment.

Gallstones and cholecystitis were reported in adult injection trials. The label rates were 1.6% versus 0.7% for gallstones and 0.6% versus 0.2% for cholecystitis with Wegovy versus placebo. Upper-right abdominal pain, pain between the shoulder blades, fever, vomiting, or yellowing of the skin warrants prompt medical advice. These rates do not show that every event is caused by weight loss alone.

Acute kidney injury occurred in 7 Wegovy-treated adults (0.4 cases per 100 patient-years) and 4 placebo-treated adults (0.2 cases per 100 patient-years) in weight-reduction trials. Some events occurred with gastrointestinal symptoms or dehydration. Keep fluid intake appropriate for your own medical conditions, and contact a clinician for markedly reduced urination, dark urine, new swelling, or severe dizziness rather than trying to correct dehydration with a fixed water target.

Hypoglycemia deserves particular attention when Wegovy is used with insulin or a sulfonylurea; a prescriber may adjust the other medicine and advise glucose monitoring. People with diabetes should also discuss existing diabetic retinopathy, because rapid glucose improvement can temporarily worsen it. Wegovy is not recommended with severe gastroparesis. Tell the anesthesia or procedural team before surgery or deep sedation: rare aspiration cases have been reported despite fasting, and the team should decide the preparation and medication plan. Never share a FlexTouch pen even with a new needle.

The label reports a mean resting-heart-rate increase of about 1 to 4 beats per minute versus placebo. Report sustained palpitations or a persistent increase to the prescribing clinician; the label directs discontinuation when a sustained increase is confirmed. These precautions are reasons for individualized follow-up, not a reason to assume that a serious event will occur.

Mental Health Monitoring and Psychiatric Considerations

The FDA's January 2026 review, including 91 placebo-controlled trials involving 107,910 patients, found no increased risk of suicidal ideation or behavior with GLP-1 receptor agonists. Wegovy's prescribing information records removal of that warning in January 2026. This is reassuring evidence; new mood symptoms still deserve attention regardless of their cause.

Tell your prescriber or a mental-health professional about new or worsening depression, anxiety, irritability, sleep changes, loss of interest, or thoughts of self-harm. Call or text 988 in the United States for crisis support, and call 911 or emergency services for immediate danger. A clinician can help assess symptoms and the support you need.

Cardiovascular Benefits from the SELECT Trial

SELECT was a randomized, placebo-controlled cardiovascular-outcomes trial of 17,604 adults at least 45 years old with BMI at least 27 kg/m2, established cardiovascular disease, and no history of diabetes. Participants received weekly semaglutide 2.4 mg or placebo, with mean follow-up of 39.8 months. The primary endpoint was time to a first major adverse cardiovascular event (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The primary SELECT report recorded MACE in 6.5% versus 8.0% of participants, hazard ratio 0.80 (95% CI 0.72-0.90), an observed difference of about 1.5 percentage points.

The commonly quoted 20% figure is a relative reduction in that composite hazard, not a 20-percentage-point reduction and not a separate 20% reduction established for each component. It applies to the selected SELECT population and does not promise that every person taking Wegovy will have the same benefit.

Later prespecified adiposity and mediation analyses examined whether weight, waist circumference, inflammation, glucose, lipids, blood pressure, and other measured factors explained the result. They suggest that measured weight loss does not fully account for the observed MACE reduction, but these are post-randomization, model-based analyses with wide and sometimes unstable intervals. They do not prove a direct weight-independent mechanism or establish a fixed percentage of benefit that is independent of weight loss. See the adiposity analysis and the 2026 mediation analysis for their limits.

Long-Term Safety Considerations and Durability

Longer studies provide useful context but cannot prove that rare harms will never occur or that treatment will be equally tolerable for life. In the four-year SELECT weight analysis, adults with established cardiovascular disease, overweight or obesity, and no diabetes had mean weight change of -10.2% with semaglutide versus -1.5% with placebo at week 208. This is a different population and purpose from the STEP weight-management trials; the long-term SELECT analysis reports its safety and anthropometry by BMI category.

Hair loss was reported in 3.3% of participants receiving 2.4-mg Wegovy in the pooled adult injection trials versus 1.0% with placebo and was associated with weight reduction. If it is persistent or troubling, discuss nutrition and other possible causes with a clinician. Timing and recovery vary, and adequate protein does not guarantee prevention.

Weight may return after treatment stops. An exploratory STEP 1 extension included 327 participants from the semaglutide and placebo groups. Treatment and the study lifestyle intervention ended at week 68. Among participants previously assigned semaglutide, prior weight loss averaged 17.3% and 11.6 percentage points were regained by week 120, leaving a net loss of about 5.6%. That subset is informative but does not predict the outcome for every person. It also does not establish that every gastrointestinal symptom resolves within days; persistent symptoms need review.

Serious Warnings: When to Call Doctor or Seek Emergency Care

Contact the prescribing clinician promptly for vomiting or diarrhea that prevents adequate fluids, reduced urination, dark urine, persistent or severe constipation, sustained palpitations, new mood symptoms, or possible gallbladder pain. Ask what to do about a dose rather than delaying or repeating it on your own.

Stop Wegovy and seek emergency help for trouble breathing or swallowing, or swelling of the face, lips, tongue, or throat, which can signal a serious allergic reaction. Emergency evaluation is also appropriate for severe abdominal pain, vomiting blood or material that looks like coffee grounds, black or bloody stools, fainting, confusion, or severe dehydration. For thoughts of self-harm or a mental-health crisis, call or text 988; call 911 or emergency services for immediate danger.

A possible pancreatitis or severe allergic reaction should not be managed by waiting for a routine appointment. Bring the product name, dose, other medicines, and the timing of the last dose to the clinician or emergency team.

Management Strategies for Optimal Tolerability

A multidisciplinary expert consensus offers practical ways to manage common symptoms: eat small, slow meals, stop when comfortably full, choose bland, lower-fat foods while nausea is active, and avoid lying down soon after eating. Crackers, toast, broth, rice, or other foods you tolerate can be useful short-term choices. Keep a simple record of your own triggers rather than planning around a fixed post-injection symptom window.

Sip fluids as tolerated and within any kidney, heart, or other fluid restriction given by your clinician. For constipation, gradual fiber and gentle activity may help when tolerated; severe, persistent, or painful constipation needs assessment. Ginger foods or drinks are an expert-consensus comfort option for some people. If symptoms need medication, a clinician or pharmacist can help select an anti-nausea medicine, laxative, or antidiarrheal appropriate to the symptom, other medicines, and medical history.

The labeled injection schedule uses four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, and maintenance from week 17. If a dose is not tolerated, the prescribing information allows consideration of delaying escalation for four weeks. Ask the prescriber to adjust the pace rather than increasing while significant symptoms persist.

Protein-rich foods such as Greek yogurt, eggs, fish, lean poultry, or legumes can help meet an individualized nutrition plan. A joint nutrition advisory discusses proposed protein targets of 1.2–1.6 g/kg/day during active weight reduction, while noting uncertainty over which body-weight measure to use in obesity. A dietitian or clinician can tailor the target, especially with kidney disease. Pair adequate nutrition with resistance training suited to your ability: protein alone is generally insufficient to preserve muscle optimally.

Wegovy Versus Ozempic Side Effects: Key Differences

Wegovy and Ozempic both contain semaglutide, but they are labeled for different purposes and their trials cannot be treated as head-to-head comparisons. Wegovy is used for chronic weight management and, in a specified adult population, cardiovascular risk reduction. Ozempic's prescribing information covers type 2 diabetes and related cardiovascular or kidney outcomes. Coverage and out-of-pocket cost also vary by indication, plan, and program.

Both injections start at 0.25 mg once weekly for four weeks. For adult weight management, Wegovy then progresses through 0.5 mg, 1 mg, and 1.7 mg before maintenance at 1.7 or 2.4 mg, with 2.4 mg recommended; 7.2 mg is conditional on tolerating 2.4 mg for at least four weeks and needing additional clinically indicated weight reduction. Ozempic can increase from 0.5 mg to 1 mg and then 2 mg after at least four weeks at a dose when additional glycemic control is needed, with a 2-mg maximum.

Separate studies do not establish that one product has fewer gastrointestinal effects, a better initial tolerability profile, or identical nausea, vomiting, diarrhea, and constipation frequencies. Use the product and dose prescribed for its indication, and ask the prescriber before changing products or schedules.

Frequently Asked Questions About Wegovy Side Effects